CA-CEQUENCE-SECURITY
7.4.2022 16:02:08 CEST | Business Wire | Press release
Cequence Security , the industry leader in API security, today announced a strategic partnership with Software AG , the software pioneer of a truly connected world. The integration of API Security Platform with Software AG’s webMethods Gateway will establish an end-to-end API security solution for enterprise security teams.
“Our goal has always been to empower our customers to become truly connected and secured enterprises,” said Jason Johns, Head of Global Alliances and Channels at Software AG. “We’ve been doing this for over 50 years, but the era of digital transformation brought about by COVID-19 has highlighted the market need for a solution that protects against attacks targeting API vulnerabilities, attempts to commit fraud or access to sensitive information. Our partnership with Cequence Security will offer that robust API security protection that the industry has been lacking.”
APIs are now the cornerstone of applications, allowing organizations to adopt a more iterative development methodology where applications are released and updated with greater frequency. The Software AG webMethods Gateway allows customers to centrally manage their APIs, enforce access control and prevent volumetric traffic spikes. The Cequence API Security Platform complements and extends the webMethods capabilities with holistic API attack surface area discovery, misuse and attack detection and is the only solution available that natively mitigates API attacks in real-time.
Historically, organizations have relied on their perimeter security services to protect their APIs. This trend has changed: over 80% of the attacks Cequence Security blocked between July and December 2021 were targeting APIs. This integration will give security teams more visibility into the use of security features available as part of the webMethods Gateway, and more insight into the requests targeting their APIs, enabling them to find and stop threats before they impact the business.
“We are very excited to partner with Cequence Security to better address the growing need for enhanced API security in today’s digital business climate. Their comprehensive API security platform combines visibility and risk assessment to protect and prevent sophisticated attacks. Together with Software AG’s API management capabilities, our new partnership with Cequence Security will help organizations discover and better protect their APIs against all types of threats.” – Suraj Kumar, General Manager API, Integration & Microservices, Software AG
“Research has shown a drastic uptick in data breaches and attacks targeted at APIs over the past year, and our mission is to give enterprises an easy button for all things API security-related through strategic integrations,” said Larry Link, President and CEO of Cequence Security. “We’re thrilled to partner with Software AG to extend their capabilities and carry out our dual mission to enable enterprises to successfully grow their revenue without the fear of API attacks.”
About Cequence Security
Organizations trust Cequence Security to protect their APIs and web applications with the most effective and adaptive defense against online fraud, business logic attacks, exploits and unintended data leakage, which enables them to remain resilient in today’s ever-changing business and threat landscape. Cequence Security provides the only API Security Platform offering that unifies API discovery, inventory tracking, risk analysis and native remediation with proven, real-time threat protection against ever evolving online attacks. Learn more at www.cequence.ai
About Software AG
Software AG is the software pioneer of a truly connected world. Since 1969, it has helped 10,000+ organizations use software to connect people, departments, systems and devices. Software AG empowers truly connected enterprises using integration & APIs, IoT & analytics and business & IT transformation. Software AG’s products establish a fluid flow of data that allows everything and everyone to work together. The company has more than 4,800 employees across more than 70 countries and annual revenue of over €800m. It is committed to its ambition of exceeding €1 billion of revenue and reaching an operating profit margin (EBITA, non-IFRS) of between 25 percent to 30 percent in 2023. For more information, also follow on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005170/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
